Travere Therapeutics (TVTX) Operating Expenses (2011 - 2026)

Travere Therapeutics has reported Operating Expenses for 16 years, with the latest figure at $164.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 31.92% year-over-year to $164.1 million; the trailing twelve-month figure through Mar 2026 stood at $593.3 million (up 18.46% YoY), and the FY2025 full-year result was $553.6 million, down 0.62% from the prior year.
• Operating Expenses for Q1 2026 stood at $164.1 million, up from $162.1 million in the prior quarter.
• The five-year high for Operating Expenses was $180.6 million in Q1 2024, with the low at $95.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $131.6 million across 5 years, with a median of $128.3 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 149.85% — and 2025, when it plunged 31.12%.
• Travere Therapeutics' Operating Expenses stood at $116.0 million in 2022, then grew by 20.04% to $139.3 million in 2023, then retreated by 2.71% to $135.5 million in 2024, then grew by 19.62% to $162.1 million in 2025, then grew by 1.23% to $164.1 million in 2026.
• The last three Operating Expenses figures came in at $164.1 million (Q1 2026), $162.1 million (Q4 2025), and $139.9 million (Q3 2025), per Business Quant data.